Tarsier Pharma's pending NYSE American IPO, with amended F-1 filings through mid-July 2026 targeting a $45-50 million raise at $8-10 per share, has not resulted in an effective listing or first-day trading as of late August. This absence of progress underpins the 98.7% market-implied probability of no IPO before September 2026, reflecting standard delays for small-cap clinical-stage biotechs amid volatile equity conditions and execution risks around the Phase 3 Tarsier-04 trial. Trader consensus prices in typical timelines for SEC review and market sentiment rather than immediate completion. An unexpected acceleration in regulatory clearance or favorable sector conditions could still shift outcomes toward one of the low-probability valuation buckets near $250-450 million.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日2026年9月以前にIPOなし 98.6%
4億ドル～4億5千万ドル <1%
2億5,000万ドル未満 <1%
2億5千万ドル〜3億ドル <1%
$16,573 Vol.
$16,573 Vol.
2026/08/31
2億5,000万ドル未満
<1%
2億5千万ドル〜3億ドル
<1%
3億ドル〜3億5千万ドル
<1%
3億5000万ドル〜4億ドル
<1%
4億ドル～4億5千万ドル
<1%
4億5,000万ドル超
<1%
2026年9月以前にIPOなし
99%
2026年9月以前にIPOなし 98.6%
4億ドル～4億5千万ドル <1%
2億5,000万ドル未満 <1%
2億5千万ドル〜3億ドル <1%
$16,573 Vol.
$16,573 Vol.
2026/08/31
2億5,000万ドル未満
$1,099 Vol.
<1%
2億5千万ドル〜3億ドル
$1,079 Vol.
<1%
3億ドル〜3億5千万ドル
$866 Vol.
<1%
3億5000万ドル〜4億ドル
$761 Vol.
<1%
4億ドル～4億5千万ドル
$594 Vol.
<1%
4億5,000万ドル超
$680 Vol.
<1%
2026年9月以前にIPOなし
$11,495 Vol.
99%
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's pending NYSE American IPO, with amended F-1 filings through mid-July 2026 targeting a $45-50 million raise at $8-10 per share, has not resulted in an effective listing or first-day trading as of late August. This absence of progress underpins the 98.7% market-implied probability of no IPO before September 2026, reflecting standard delays for small-cap clinical-stage biotechs amid volatile equity conditions and execution risks around the Phase 3 Tarsier-04 trial. Trader consensus prices in typical timelines for SEC review and market sentiment rather than immediate completion. An unexpected acceleration in regulatory clearance or favorable sector conditions could still shift outcomes toward one of the low-probability valuation buckets near $250-450 million.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
マーケット開始日： Jul 7, 2026, 9:12 AM ET
音量
$16,573終了日
2026/09/01マーケット開始日
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Tarsier Pharma's pending NYSE American IPO, with amended F-1 filings through mid-July 2026 targeting a $45-50 million raise at $8-10 per share, has not resulted in an effective listing or first-day trading as of late August. This absence of progress underpins the 98.7% market-implied probability of no IPO before September 2026, reflecting standard delays for small-cap clinical-stage biotechs amid volatile equity conditions and execution risks around the Phase 3 Tarsier-04 trial. Trader consensus prices in typical timelines for SEC review and market sentiment rather than immediate completion. An unexpected acceleration in regulatory clearance or favorable sector conditions could still shift outcomes toward one of the low-probability valuation buckets near $250-450 million.
This market will resolve based on Tarsier Pharma's market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on July 9 (ET). If no such IPO occurs by August 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before September 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
音量
$16,573終了日
2026/09/01マーケット開始日
Jul 7, 2026, 9:12 AM ETResolver
0x69c47De9D...Tarsier Pharma's pending NYSE American IPO, with amended F-1 filings through mid-July 2026 targeting a $45-50 million raise at $8-10 per share, has not resulted in an effective listing or first-day trading as of late August. This absence of progress underpins the 98.7% market-implied probability of no IPO before September 2026, reflecting standard delays for small-cap clinical-stage biotechs amid volatile equity conditions and execution risks around the Phase 3 Tarsier-04 trial. Trader consensus prices in typical timelines for SEC review and market sentiment rather than immediate completion. An unexpected acceleration in regulatory clearance or favorable sector conditions could still shift outcomes toward one of the low-probability valuation buckets near $250-450 million.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問